You are here

TGA Internet site archive

The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.

CMEC Meeting 34, 3 May 2002

Complementary Medicines Evaluation Committee

3 May 2002

Extracted ratified minutes

How to access a pdf document

CMEC Meeting 34 extracted ratified minutes (pdf,117kb)

Public recommendation summary

This summary has been posted immediately after the CMEC meeting to give quick advice of the recommendations made by CMEC to the TGA. This summary does not represent the decisions of TGA. Reasons underlying these recommendations will be available after Members ratify the Minutes at the next CMEC meeting.

Item 2 Minutes of CMEC's 33rd Meeting

Recommendation 34.1

CMEC confirms that the draft Minutes of its previous meeting (CMEC 33, 15 March 2002), as amended, are a true and accurate record of that previous meeting.

Item 4.1 Working Party on Herbal Medicine Issues

Recommendation 34.2

CMEC recommends to the TGA that the paper prepared by the CMEC Working Party on Herbal Medicine Issues be incorporated into the consultation paper which will then be considered by CMEC at its next meeting.

Item 5.3 Caffeine content in herbal ingredients

Recommendation 34.4

CMEC recommends to the TGA that labels on products containing those herbs identified as containing caffeine be required to declare:

  • that the goods contain caffeine; and
  • the total quantity of caffeine per dosage unit.

Homoeopathic medicines more dilute than 1X (mother tinctures) are exempt from this requirement.

Item 6.1 L-arginine

Recommendation 34.6

CMEC recommends to the TGA that L-arginine is suitable for use as an active ingredient for use in listable therapeutic goods, with the condition that it is for topical application only, and not for mucosal, vaginal or rectal use.

Item 6.2 Red yeast rice

Recommendation 34.7

CMEC recommends to the TGA that red yeast rice is not suitable for use as an active ingredient in listable therapeutic goods as the safety associated with its use in these goods could not be established on the evidence provided to the Committee.

Top of page